# LPXN

## Overview
Leupaxin (LPXN) is a gene that encodes the leupaxin protein, a member of the paxillin family of cytoskeletal adaptor proteins. The leupaxin protein is characterized by its structural domains, including LD motifs and LIM domains, which facilitate its role in cellular signaling and adhesion processes (Dai2009LPXN; KAULFUSS2015Leupaxin). As an adaptor protein, leupaxin is involved in integrin signaling and is crucial for the recruitment of signaling molecules to focal adhesions, impacting cell motility and adhesion (yao2018examination). It plays a significant role in immune cell function, particularly in cytotoxic T lymphocytes, and is implicated in various cancer pathways, acting as a coactivator for hormone receptors and influencing cancer cell proliferation and migration (Kaulfuss2008Leupaxin; Teng2023Elucidating). The gene's expression and the protein's interactions are of clinical interest, particularly in the context of cancer progression and potential therapeutic targeting (Kaulfuss2008Leupaxin).

## Structure
Leupaxin (LPXN) is a member of the paxillin superfamily of adaptor proteins, characterized by its distinct structural domains. The LPXN protein is composed of 386 amino acids and includes three LD motifs at the N-terminus and four LIM domains at the C-terminus (Dai2009LPXN). The LD motifs, each consisting of 13 amino acids, are leucine-rich domains that facilitate protein-protein interactions. The LIM domains, named after LIN-11, Isl1, and MEC-3, are zinc-finger motifs, each comprising 56 amino acids, which also mediate protein interactions (Dai2009LPXN; KAULFUSS2015Leupaxin).

Leupaxin's structure allows it to function as an adaptor platform, transmitting signals from the cell surface to the nucleus, influencing transcriptional regulation (KAULFUSS2015Leupaxin). The protein is subject to post-translational modifications, such as phosphorylation, which can affect its function and interactions. In the context of cancer, leupaxin interacts with estrogen receptors, particularly ERα, through its LIM domains, enhancing transcriptional activity (KAULFUSS2015Leupaxin). The LD4 motif is crucial for nuclear export, highlighting its role in cellular localization and function (KAULFUSS2015Leupaxin).

## Function
Leupaxin (LPXN) is a cytoskeletal adaptor protein that plays a significant role in integrin signaling and cellular adhesion processes, particularly in cytotoxic T lymphocytes (CTLs). It is a member of the paxillin family and is involved in recruiting signaling molecules to focal adhesions, which are crucial for cell motility and adhesion (yao2018examination). In CTLs, leupaxin is rapidly recruited to the immunological synapse upon LFA-1 engagement with ICAM-1, facilitating the movement of the microtubule-organizing center (MTOC) towards the membrane during CTL-target cell conjugation. This process is essential for optimal TCR signaling and CTL degranulation (yao2018examination).

Leupaxin is also involved in the phosphorylation of signaling proteins, such as Pyk2, which is crucial for normal CTL adhesion and activation (yao2018examination). It interacts with Src family kinases, and its phosphorylation is influenced by these interactions, playing a role in signaling pathways (yao2018examination). Leupaxin's role in cell adhesion and migration is further highlighted by its involvement in focal adhesion-like structures and its dynamic nature at the MTOC, suggesting its importance in cellular dynamics and motility (yao2018examination).

## Clinical Significance
Leupaxin (LPXN) has been implicated in the progression of several cancers due to alterations in its expression levels and interactions. In esophageal squamous cell carcinoma (ESCC), LPXN is overexpressed compared to normal tissues, and its high expression is associated with poor prognosis and worse survival outcomes. This overexpression correlates with increased cell proliferation, migration, and invasion, while knockdown of LPXN results in decreased cell viability and increased apoptosis. LPXN's interaction with immune checkpoint proteins like PD-L1 suggests its role in immune system pathways and potential drug resistance, making it a candidate for immunotherapy targeting in ESCC (Teng2023Elucidating).

In prostate cancer, LPXN acts as a coactivator of the androgen receptor (AR) and is overexpressed in cancerous tissues compared to normal prostate tissues. Its expression correlates with higher Gleason scores, indicating more aggressive tumors. LPXN influences cell adhesion, invasion, and motility, and its down-regulation leads to reduced invasiveness and migration in prostate cancer cell lines. These findings suggest that LPXN could serve as a progression marker and a potential therapeutic target for advanced prostate cancer (Kaulfuss2008Leupaxin).

## Interactions
Leupaxin (LPXN) is a member of the paxillin protein family and is involved in various protein interactions that influence cell signaling and adhesion. In prostate cancer cells, leupaxin acts as a coactivator of the androgen receptor (AR), interacting with AR in a ligand-dependent manner. This interaction is facilitated by the LIM domains of leupaxin, particularly LIM domains 3 and 4, which are crucial for AR binding (Kaulfuss2008Leupaxin). Leupaxin also interacts with focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2), playing a role in the formation of adhesion zones (Kaulfuss2008Leupaxin).

In breast cancer cells, leupaxin interacts with estrogen receptors α (ERα) and β (ERβ). The interaction with ERα is estrogen-dependent, while it can bind to ERβ regardless of estrogen presence. This interaction enhances the transcriptional activity of ERα, particularly in the presence of estradiol (KAULFUSS2015Leupaxin). Leupaxin's interaction with these receptors involves its LIM domains and is crucial for its role as a transcriptional activator (KAULFUSS2015Leupaxin).

In cytotoxic T lymphocytes, leupaxin is recruited to the immunological synapse, where it interacts with LFA-1 and is involved in signaling pathways mediated by Pyk2 and ERK (yao2018examination).


## References


1. (Teng2023Elucidating) Elucidating the Correlation between Leupaxin as a Prognostic Biomarker and Immunotherapeutic Efficacy in Esophageal Squamous Cell Carcinoma. This article has 0 citations.

[2. (Kaulfuss2008Leupaxin) Silke Kaulfuss, Michal Grzmil, Bernhard Hemmerlein, Paul Thelen, Stefan Schweyer, Jürgen Neesen, Lukas Bubendorf, Andrew G. Glass, Hubertus Jarry, Bernd Auber, and Peter Burfeind. Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells. Molecular Endocrinology, 22(7):1606–1621, July 2008. URL: http://dx.doi.org/10.1210/me.2006-0546, doi:10.1210/me.2006-0546. This article has 31 citations.](https://doi.org/10.1210/me.2006-0546)

3. (yao2018examination) Examination of the Localization and Function of the Protein Leupaxin in Cytotoxic T Lymphocytes. This article has 0 citations.

[4. (Dai2009LPXN) Hai‐Ping Dai, Yong‐Quan Xue, Jian‐Wei Zhou, Ai‐Ping Li, Ya‐Fang Wu, Jin‐Lan Pan, Yong Wang, and Jun Zhang. Lpxn, a member of the paxillin superfamily, is fused to runx1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation. Genes, Chromosomes and Cancer, 48(12):1027–1036, September 2009. URL: http://dx.doi.org/10.1002/gcc.20704, doi:10.1002/gcc.20704. This article has 12 citations.](https://doi.org/10.1002/gcc.20704)

[5. (KAULFUSS2015Leupaxin) SILKE KAULFUSS, ANNA-MARIA HERR, ANJA BÜCHNER, BERNHARD HEMMERLEIN, ANDREAS R. GÜNTHERT, and PETER BURFEIND. Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor α. International Journal of Oncology, 47(1):106–114, May 2015. URL: http://dx.doi.org/10.3892/ijo.2015.2988, doi:10.3892/ijo.2015.2988. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2015.2988)